Biopharma R&D Partnerships: From David & Goliath to Networked R&D

3.67 avg rating
( 3 ratings by Goodreads )
 
9780993518102: Biopharma R&D Partnerships: From David & Goliath to Networked R&D
View all copies of this ISBN edition:
 
 

This book is about asymmetric “David & Goliath” partnerships in pharmaceutical R&D—bilateral arrangements in which one partner is a smaller bioscience or academic organization (David) and the other a large multinational corporation (Goliath). The past decade has seen a paradigm shift in how medicines and other therapies are discovered, developed and commercialized. The new distributed model of R&D seamlessly blends external partnerships with in-house efforts to generate innovative medicines and create new value.

Smaller bioscience firms and academia have been both beneficiaries and targets of this fundamental change. Partnering with giant pharmaceutical corporations can provide the resources and channels to market that an academic laboratory or smaller company simply does not have, but this approach also brings unexpected challenges and new demands. We explore those factors that most influence the emergence of valuable outcomes from such partnerships. In particular, we will adopt in many cases the David perspective, focusing on issues and challenges of most concern to the small partner in such arrangements. If these asymmetric partnerships are to deliver real value for both sides, the Davids in these David & Goliath partnerships must develop the practices and mindset to face these issues and challenges head-on. This book seeks to address this need, drawing upon the partnering experiences and perspectives of more than forty different companies and organizations which the author has either worked closely with or interviewed.

After an introductory chapter on how the large pharmaceutical companies have transformed their R&D model, the remaining eleven chapters are organized as three parts. Part A introduces foundation concepts and provides a framework for understanding David & Goliath partnerships. Chapter 2 describes the dynamics of biopharma R&D projects. Chapter 3 discusses execution risk, collaboration risk, collaboration tax, and the financial mechanisms used to share risk and return. Chapter 4 characterizes the different bilateral R&D partnership models. Chapter 5 describes archetypes of collaborating organizations and what drives their behavior in partnerships.

Part B dives into the practical aspects of David & Goliath R&D partnerships, looking at what can be done to improve the odds of beneficial outcomes emerging. Chapter 6 considers how organizations select, design and negotiate partnerships. Chapter 7 discusses important considerations in how the project will be organized, conducted, and governed, and by whom. Chapter 8 concentrates on the execution phase, beginning with the honeymoon period, before discussing the inevitable stage transitions and concluding with a look at the periodic maintenance actions needed to keep a partnership healthy. Chapter 9 delves into the key role alliance managers play—the processes they oversee and the problematic situations they are called upon to resolve; we also discuss what makes a good alliance manager.

Part C highlights some important trends with respect to collaboration in the biopharma R&D ecosystem. Chapter 10 looks at the efforts of large multinational corporations to upgrade their partnering-related activities by establishing corporate alliance management functions, institutionalizing a common platform of alliance management practices, and scouting for innovations through relationship building and networking. Chapter 11 looks at the increasing role played by academia and nonprofit organizations in biopharma R&D, as llustrated by the growth of strategic industry-academic co-discovery alliances and nonprofit drug discovery organizations. Chapter 12 looks at two alternative paths for building networked R&D organizations that excel at operating partnerships.

"synopsis" may belong to another edition of this title.

About the Author:

Robert Thong consults, speaks and writes on business strategy, collaborations and change in the bioscience sector. Over the past twenty-five years, he has worked with more than one hundred different pharmaceutical, biotech, medical device and healthcare organizations.

"About this title" may belong to another edition of this title.

Buy New View Book
List Price: US$ 35.99
US$ 33.80

Convert Currency

Shipping: FREE
From United Kingdom to U.S.A.

Destination, Rates & Speeds

Add to Basket

Other Popular Editions of the Same Title

9780993518133: Biopharma R&D Partnerships: From David & Goliath to Networked R&D

Featured Edition

ISBN 10:  0993518133 ISBN 13:  9780993518133
Publisher: Phizz Rx Publishing, 2016
Hardcover

Top Search Results from the AbeBooks Marketplace

1.

Robert Thong
Published by Phizz Rx Publishing, United Kingdom (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Paperback Quantity Available: 10
Print on Demand
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Phizz Rx Publishing, United Kingdom, 2016. Paperback. Condition: New. Language: English . Brand New Book ***** Print on Demand *****.This book is about asymmetric David Goliath partnerships in pharmaceutical RD--bilateral arrangements in which one partner is a smaller bioscience or academic organization (David) and the other a large multinational corporation (Goliath). The past decade has seen a paradigm shift in how medicines and other therapies are discovered, developed and commercialized. The new distributed model of RD seamlessly blends external partnerships with in-house efforts to generate innovative medicines and create new value. Smaller bioscience firms and academia have been both beneficiaries and targets of this fundamental change. Partnering with giant pharmaceutical corporations can provide the resources and channels to market that an academic laboratory or smaller company simply does not have, but this approach also brings unexpected challenges and new demands. We explore those factors that most influence the emergence of valuable outcomes from such partnerships. In particular, we will adopt in many cases the David perspective, focusing on issues and challenges of most concern to the small partner in such arrangements. If these asymmetric partnerships are to deliver real value for both sides, the Davids in these David Goliath partnerships must develop the practices and mindset to face these issues and challenges head-on. This book seeks to address this need, drawing upon the partnering experiences and perspectives of more than forty different companies and organizations which the author has either worked closely with or interviewed. After an introductory chapter on how the large pharmaceutical companies have transformed their RD model, the remaining eleven chapters are organized as three parts. Part A introduces foundation concepts and provides a framework for understanding David Goliath partnerships. Chapter 2 describes the dynamics of biopharma RD projects. Chapter 3 discusses execution risk, collaboration risk, collaboration tax, and the financial mechanisms used to share risk and return. Chapter 4 characterizes the different bilateral RD partnership models. Chapter 5 describes archetypes of collaborating organizations and what drives their behavior in partnerships. Part B dives into the practical aspects of David Goliath RD partnerships, looking at what can be done to improve the odds of beneficial outcomes emerging. Chapter 6 considers how organizations select, design and negotiate partnerships. Chapter 7 discusses important considerations in how the project will be organized, conducted, and governed, and by whom. Chapter 8 concentrates on the execution phase, beginning with the honeymoon period, before discussing the inevitable stage transitions and concluding with a look at the periodic maintenance actions needed to keep a partnership healthy. Chapter 9 delves into the key role alliance managers play--the processes they oversee and the problematic situations they are called upon to resolve; we also discuss what makes a good alliance manager. Part C highlights some important trends with respect to collaboration in the biopharma RD ecosystem. Chapter 10 looks at the efforts of large multinational corporations to upgrade their partnering-related activities by establishing corporate alliance management functions, institutionalizing a common platform of alliance management practices, and scouting for innovations through relationship building and networking. Chapter 11 looks at the increasing role played by academia and nonprofit organizations in biopharma RD, as llustrated by the growth of strategic industry-academic co-discovery alliances and nonprofit drug discovery organizations. Chapter 12 looks at two alternative paths for building networked RD organizations that excel at operating partnerships. Seller Inventory # AAV9780993518102

More information about this seller | Contact this seller

Buy New
US$ 33.80
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

2.

Robert Thong
Published by Phizz Rx Publishing, United Kingdom (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Paperback Quantity Available: 10
Print on Demand
Seller:
Book Depository International
(London, United Kingdom)
Rating
[?]

Book Description Phizz Rx Publishing, United Kingdom, 2016. Paperback. Condition: New. Language: English . Brand New Book ***** Print on Demand *****. This book is about asymmetric David Goliath partnerships in pharmaceutical RD--bilateral arrangements in which one partner is a smaller bioscience or academic organization (David) and the other a large multinational corporation (Goliath). The past decade has seen a paradigm shift in how medicines and other therapies are discovered, developed and commercialized. The new distributed model of RD seamlessly blends external partnerships with in-house efforts to generate innovative medicines and create new value. Smaller bioscience firms and academia have been both beneficiaries and targets of this fundamental change. Partnering with giant pharmaceutical corporations can provide the resources and channels to market that an academic laboratory or smaller company simply does not have, but this approach also brings unexpected challenges and new demands. We explore those factors that most influence the emergence of valuable outcomes from such partnerships. In particular, we will adopt in many cases the David perspective, focusing on issues and challenges of most concern to the small partner in such arrangements. If these asymmetric partnerships are to deliver real value for both sides, the Davids in these David Goliath partnerships must develop the practices and mindset to face these issues and challenges head-on. This book seeks to address this need, drawing upon the partnering experiences and perspectives of more than forty different companies and organizations which the author has either worked closely with or interviewed. After an introductory chapter on how the large pharmaceutical companies have transformed their RD model, the remaining eleven chapters are organized as three parts. Part A introduces foundation concepts and provides a framework for understanding David Goliath partnerships. Chapter 2 describes the dynamics of biopharma RD projects. Chapter 3 discusses execution risk, collaboration risk, collaboration tax, and the financial mechanisms used to share risk and return. Chapter 4 characterizes the different bilateral RD partnership models. Chapter 5 describes archetypes of collaborating organizations and what drives their behavior in partnerships. Part B dives into the practical aspects of David Goliath RD partnerships, looking at what can be done to improve the odds of beneficial outcomes emerging. Chapter 6 considers how organizations select, design and negotiate partnerships. Chapter 7 discusses important considerations in how the project will be organized, conducted, and governed, and by whom. Chapter 8 concentrates on the execution phase, beginning with the honeymoon period, before discussing the inevitable stage transitions and concluding with a look at the periodic maintenance actions needed to keep a partnership healthy. Chapter 9 delves into the key role alliance managers play--the processes they oversee and the problematic situations they are called upon to resolve; we also discuss what makes a good alliance manager. Part C highlights some important trends with respect to collaboration in the biopharma RD ecosystem. Chapter 10 looks at the efforts of large multinational corporations to upgrade their partnering-related activities by establishing corporate alliance management functions, institutionalizing a common platform of alliance management practices, and scouting for innovations through relationship building and networking. Chapter 11 looks at the increasing role played by academia and nonprofit organizations in biopharma RD, as llustrated by the growth of strategic industry-academic co-discovery alliances and nonprofit drug discovery organizations. Chapter 12 looks at two alternative paths for building networked RD organizations that excel at operating partnerships. Seller Inventory # AAV9780993518102

More information about this seller | Contact this seller

Buy New
US$ 35.52
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

3.

Robert Thong
Published by Phizz Rx Publishing (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Quantity Available: > 20
Print on Demand
Seller:
Pbshop
(Wood Dale, IL, U.S.A.)
Rating
[?]

Book Description Phizz Rx Publishing, 2016. PAP. Condition: New. New Book. Shipped from US within 10 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # IQ-9780993518102

More information about this seller | Contact this seller

Buy New
US$ 31.54
Convert Currency

Add to Basket

Shipping: US$ 3.99
Within U.S.A.
Destination, Rates & Speeds

4.

Thong, Robert
Published by Phizz Rx Publishing (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Paperback Quantity Available: 1
Print on Demand
Seller:
Ria Christie Collections
(Uxbridge, United Kingdom)
Rating
[?]

Book Description Phizz Rx Publishing, 2016. Paperback. Condition: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Seller Inventory # ria9780993518102_lsuk

More information about this seller | Contact this seller

Buy New
US$ 33.81
Convert Currency

Add to Basket

Shipping: US$ 5.14
From United Kingdom to U.S.A.
Destination, Rates & Speeds

5.

Thong, Robert
Published by Phizz RX Publishing 1/5/2016 (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Paperback or Softback Quantity Available: 10
Seller:
BargainBookStores
(Grand Rapids, MI, U.S.A.)
Rating
[?]

Book Description Phizz RX Publishing 1/5/2016, 2016. Paperback or Softback. Condition: New. Biopharma R&d Partnerships: From David & Goliath to Networked R&d. Book. Seller Inventory # BBS-9780993518102

More information about this seller | Contact this seller

Buy New
US$ 41.96
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds

6.

Thong, Robert
Published by Phizz Rx Publishing (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Quantity Available: > 20
Print on Demand
Seller:
Books2Anywhere
(Fairford, GLOS, United Kingdom)
Rating
[?]

Book Description Phizz Rx Publishing, 2016. PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # LQ-9780993518102

More information about this seller | Contact this seller

Buy New
US$ 30.14
Convert Currency

Add to Basket

Shipping: US$ 11.98
From United Kingdom to U.S.A.
Destination, Rates & Speeds

7.

Thong, Robert
Published by Phizz Rx Publishing (2018)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Paperback Quantity Available: 18
Print on Demand
Seller:
Murray Media
(North Miami Beach, FL, U.S.A.)
Rating
[?]

Book Description Phizz Rx Publishing, 2018. Paperback. Condition: New. Never used! This item is printed on demand. Seller Inventory # 0993518109

More information about this seller | Contact this seller

Buy New
US$ 43.26
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds

8.

Robert Thong
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Quantity Available: 5
Seller:
ReadWhiz
(Portland, OR, U.S.A.)
Rating
[?]

Book Description Condition: New. Seller Inventory # ria9780993518102_ing

More information about this seller | Contact this seller

Buy New
US$ 43.87
Convert Currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, Rates & Speeds

9.

Robert Thong
Published by Phizz Rx Publishing, United Kingdom (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Paperback Quantity Available: 10
Seller:
Book Depository hard to find
(London, United Kingdom)
Rating
[?]

Book Description Phizz Rx Publishing, United Kingdom, 2016. Paperback. Condition: New. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. This book is about asymmetric David Goliath partnerships in pharmaceutical RD--bilateral arrangements in which one partner is a smaller bioscience or academic organization (David) and the other a large multinational corporation (Goliath). The past decade has seen a paradigm shift in how medicines and other therapies are discovered, developed and commercialized. The new distributed model of RD seamlessly blends external partnerships with in-house efforts to generate innovative medicines and create new value. Smaller bioscience firms and academia have been both beneficiaries and targets of this fundamental change. Partnering with giant pharmaceutical corporations can provide the resources and channels to market that an academic laboratory or smaller company simply does not have, but this approach also brings unexpected challenges and new demands. We explore those factors that most influence the emergence of valuable outcomes from such partnerships. In particular, we will adopt in many cases the David perspective, focusing on issues and challenges of most concern to the small partner in such arrangements. If these asymmetric partnerships are to deliver real value for both sides, the Davids in these David Goliath partnerships must develop the practices and mindset to face these issues and challenges head-on. This book seeks to address this need, drawing upon the partnering experiences and perspectives of more than forty different companies and organizations which the author has either worked closely with or interviewed. After an introductory chapter on how the large pharmaceutical companies have transformed their RD model, the remaining eleven chapters are organized as three parts. Part A introduces foundation concepts and provides a framework for understanding David Goliath partnerships. Chapter 2 describes the dynamics of biopharma RD projects. Chapter 3 discusses execution risk, collaboration risk, collaboration tax, and the financial mechanisms used to share risk and return. Chapter 4 characterizes the different bilateral RD partnership models. Chapter 5 describes archetypes of collaborating organizations and what drives their behavior in partnerships. Part B dives into the practical aspects of David Goliath RD partnerships, looking at what can be done to improve the odds of beneficial outcomes emerging. Chapter 6 considers how organizations select, design and negotiate partnerships. Chapter 7 discusses important considerations in how the project will be organized, conducted, and governed, and by whom. Chapter 8 concentrates on the execution phase, beginning with the honeymoon period, before discussing the inevitable stage transitions and concluding with a look at the periodic maintenance actions needed to keep a partnership healthy. Chapter 9 delves into the key role alliance managers play--the processes they oversee and the problematic situations they are called upon to resolve; we also discuss what makes a good alliance manager. Part C highlights some important trends with respect to collaboration in the biopharma RD ecosystem. Chapter 10 looks at the efforts of large multinational corporations to upgrade their partnering-related activities by establishing corporate alliance management functions, institutionalizing a common platform of alliance management practices, and scouting for innovations through relationship building and networking. Chapter 11 looks at the increasing role played by academia and nonprofit organizations in biopharma RD, as llustrated by the growth of strategic industry-academic co-discovery alliances and nonprofit drug discovery organizations. Chapter 12 looks at two alternative paths for building networked RD organizations that excel at operating partnerships. Seller Inventory # LIE9780993518102

More information about this seller | Contact this seller

Buy New
US$ 45.80
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

10.

Robert Thong
Published by Phizz Rx Publishing (2016)
ISBN 10: 0993518109 ISBN 13: 9780993518102
New Softcover Quantity Available: 1
Print on Demand
Seller:
Rating
[?]

Book Description Phizz Rx Publishing, 2016. Condition: New. This item is printed on demand for shipment within 3 working days. Seller Inventory # GM9780993518102

More information about this seller | Contact this seller

Buy New
US$ 43.33
Convert Currency

Add to Basket

Shipping: US$ 3.48
From Germany to U.S.A.
Destination, Rates & Speeds

There are more copies of this book

View all search results for this book